#United States #New York #Securities Fraud #Rosen Law Firm #Aquestive Therapeutics

Investors Urged to Lead Class Action Against Aquestive Therapeutics for Securities Fraud

In a significant development for investors of Aquestive Therapeutics, Inc. (NASDAQ: AQST), the Rosen Law Firm is reminding those who purchased securities within the defined class period—from June 16, 2025, to January 8, 2026—that they may have a chance to participate in a class-action lawsuit concerning alleged securities fraud. If you bought shares of this company during the specified timeframe and suffered financial losses, you may be entitled to compensation without incurring any out-of-pocket costs.

Important Deadline Approaching

For those investors interested in taking action, there is an essential deadline on May 4, 2026, for submitting lead plaintiff motions. Acting as a lead plaintiff provides investors the opportunity to direct the litigation on behalf of all affected parties. Previous rulings have shown that being named as a lead plaintiff increases one’s influence over the lawsuit, thus enhancing the chances of successful outcomes.

How to Get Involved

If you are an investor impacted by the alleged misconduct of Aquestive Therapeutics, you can join the ongoing class action lawsuit by visiting the Rosen Law Firm’s dedicated page at this link or by contacting Phillip Kim, Esq., toll-free at 866-767-3653. Email inquiries can also be directed to contac[email protected] for further information regarding the class action.

The key issue at hand is the assertion that Aquestive Therapeutics allegedly engaged in misleading practices concerning its New Drug Application (NDA) for Anaphylm. Specifically, the lawsuit accuses the company of not adequately disclosing the real conditions of its product development process, particularly concerning the human factors involved in using its sublingual film. This lack of transparency may have caused investors to suffer significant financial losses upon the revelation of the truth.

Select an Experienced Law Firm

Choosing the right legal representation is crucial in these circumstances. The Rosen Law Firm boasts extensive experience in handling securities class actions and shareholder derivative litigation, having secured substantial settlements for investors in the past. Their record includes a noteworthy achievement of recovering over $438 million solely in 2019, demonstrating their capability and dedication to protecting investor rights.

The firm also emphasizes the importance of investing in legal counsel with a proven track record in similar cases. Many firms merely act as intermediaries without the robust experience required to effectively lead class action lawsuits.

Current Status of the Class Action

As of now, no class has been certified, which means affected investors are not represented unless they take proactive steps to engage counsel. Investors can choose to remain absent from this class while still preserving their rights to participate in any potential recoveries. It is vital for investors to be aware that joining as a lead plaintiff is not a prerequisite to benefit from any future resolutions of the case.

Stay Informed

Current and interested investors can follow updates related to this lawsuit and other important news from the Rosen Law Firm via their social media channels, including LinkedIn, Twitter, and Facebook. Keeping abreast of these developments can provide invaluable information about the legal proceedings and any related investor rights issues.

In conclusion, the opportunity to lead this class action suit against Aquestive Therapeutics is a significant step for investors affected by the alleged securities fraud. With important deadlines fast approaching, it is imperative to act promptly and choose qualified legal representation to navigate this complex landscape.